Tower Research Capital LLC TRC Has $1.23 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Tower Research Capital LLC TRC boosted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 178.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,484 shares of the biotechnology company's stock after acquiring an additional 2,233 shares during the period. Tower Research Capital LLC TRC's holdings in United Therapeutics were worth $1,229,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics during the 4th quarter worth approximately $25,000. Millstone Evans Group LLC acquired a new position in United Therapeutics during the fourth quarter worth $67,000. MassMutual Private Wealth & Trust FSB raised its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Natixis acquired a new stake in United Therapeutics in the fourth quarter valued at $85,000. Finally, Anchor Investment Management LLC boosted its position in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research note on Monday, April 21st. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Finally, StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $390.17.

United Therapeutics Trading Up 1.9 %

UTHR stock traded up $5.66 on Monday, hitting $297.04. 410,281 shares of the company's stock traded hands, compared to its average volume of 447,897. The stock has a market cap of $13.34 billion, a price-to-earnings ratio of 13.05, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 1-year low of $233.31 and a 1-year high of $417.82. The stock has a fifty day moving average of $308.67 and a 200-day moving average of $346.42.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business posted $4.36 EPS. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. The trade was a 23.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 74,500 shares of company stock worth $24,472,050. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.